Dicerna Pharmaceuticals said this week that Vin Miles has joined its board of directors.
Miles is currently a venture partner at life sciences investment group Abingworth. Prior to this, he served as senior vice president of business development for RNAi drug shop Alnylam Pharmaceuticals.
Abingworth was an early investor in Alnylam.
“Miles’ deep operating experience in the biotechnology industry and familiarity with RNAi is a tremendous asset and complement to our existing capabilities,” Dicerna CEO and Co-founder Jim Jenson said in a statement.
Silence Therapeutics said this week that CEO Jeff Vick has resigned for “personal reasons.”
The company said its board has now appointed Iain Ross, non-executive chairman, as the full-time chairman and CEO.
Silence also said that Jeremy Curnock Cook, a non-executive director, has been named senior independent non-executive director.